JP2016505023A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505023A5
JP2016505023A5 JP2015552904A JP2015552904A JP2016505023A5 JP 2016505023 A5 JP2016505023 A5 JP 2016505023A5 JP 2015552904 A JP2015552904 A JP 2015552904A JP 2015552904 A JP2015552904 A JP 2015552904A JP 2016505023 A5 JP2016505023 A5 JP 2016505023A5
Authority
JP
Japan
Prior art keywords
composition
methylxanthine
item
leucine
theophylline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015552904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505023A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011531 external-priority patent/WO2014113404A1/en
Publication of JP2016505023A publication Critical patent/JP2016505023A/ja
Publication of JP2016505023A5 publication Critical patent/JP2016505023A5/ja
Pending legal-status Critical Current

Links

JP2015552904A 2013-01-15 2014-01-14 肺の状態の処置 Pending JP2016505023A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752909P 2013-01-15 2013-01-15
US61/752,909 2013-01-15
PCT/US2014/011531 WO2014113404A1 (en) 2013-01-15 2014-01-14 Treating pulmonary conditions

Publications (2)

Publication Number Publication Date
JP2016505023A JP2016505023A (ja) 2016-02-18
JP2016505023A5 true JP2016505023A5 (enExample) 2017-02-16

Family

ID=51210014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552904A Pending JP2016505023A (ja) 2013-01-15 2014-01-14 肺の状態の処置

Country Status (6)

Country Link
US (3) US20150359771A1 (enExample)
EP (1) EP2945616B1 (enExample)
JP (1) JP2016505023A (enExample)
CN (1) CN105101958B (enExample)
AU (1) AU2014207707B2 (enExample)
WO (1) WO2014113404A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
JP2016505023A (ja) 2013-01-15 2016-02-18 ニューサート サイエンシーズ， インコーポレイテッド 肺の状態の処置
AU2014238377A1 (en) * 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
US20150013695A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
CN107998110A (zh) * 2018-01-11 2018-05-08 上海市普陀区中心医院 白藜芦醇用于制备治疗或缓解慢性气道炎症性疾病用药物的用途
US10830778B2 (en) * 2018-05-24 2020-11-10 C Technologies, Inc. Slope spectroscopy standards
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
US11437483B2 (en) 2020-03-05 2022-09-06 Intel Corporation Gate-all-around integrated circuit structures having dual nanoribbon channel structures

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4837032A (en) 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
CA2066951A1 (en) * 1991-04-26 1992-10-27 Kou Moriyama Edible composition
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
JP2002532406A (ja) 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
JP2005511210A (ja) * 2001-12-07 2005-04-28 グラクソ　グループ　リミテッド 計量バルブ及び医薬定量吸入器及びその方法
EP2301537A1 (en) 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
MXPA05000224A (es) 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
JP2006503865A (ja) * 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
JP2006516030A (ja) 2003-01-10 2006-06-15 ユニバーシタイト ファン マーストリヒト Ｃｏｐｄ及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
AU2005265031A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
WO2006049286A1 (ja) * 2004-11-02 2006-05-11 Ajinomoto Co., Inc. アレルギー性疾患予防・治療剤
RU2395285C2 (ru) 2005-02-11 2010-07-27 Арджента Дискавери Лимитед Комбинация соединений метилксантина и стероидов для лечения хронических респираторных заболеваний
WO2006138227A1 (en) 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US20110191871A1 (en) 2006-02-28 2011-08-04 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2381951B1 (en) * 2009-01-28 2015-12-23 Life Science Nutrition AS Compositions and methods of treating viral infections
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
US8173181B2 (en) * 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
EP2571499A1 (en) * 2010-05-18 2013-03-27 Mahmut Bilgic Pharmaceutical composition comprising n- acetylcysteine and a xanthine
RU2631597C2 (ru) * 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
JP2016505023A (ja) 2013-01-15 2016-02-18 ニューサート サイエンシーズ， インコーポレイテッド 肺の状態の処置
AU2014238377A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators

Similar Documents

Publication Publication Date Title
JP2016505023A5 (enExample)
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
NZ603579A (en) Controlled release formulations
JP2011225596A5 (enExample)
NZ747376A (en) High dose levodopa capsules for pulmonary use
NZ606548A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
JP2013516493A5 (enExample)
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
GB201018289D0 (en) Treatment of respiratory disorders
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
JP2013536015A5 (enExample)
JP2013505205A5 (enExample)
RU2009142937A (ru) Тапентадол для лечения в связи с остеоартрозом
JP2015038135A5 (enExample)
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
CN102858333A (zh) 呼吸紊乱的治疗
JP2016534142A5 (enExample)
IL251413B2 (en) Composition of injectable buprenorphine
HRP20180774T1 (hr) Orodisperzibilni dezmopresin za povećanje početnog razdoblja sna neometanog s nokturijom
JP2013531041A5 (enExample)
PH12013500923A1 (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
HRP20240115T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
WO2011112922A3 (en) Co-crystals and pharmaceutical formulations comprising the same
JP2012518646A5 (enExample)